4//SEC Filing
Karydas Daphne 4
Accession 0000899243-22-036295
CIK 0001664106other
Filed
Nov 16, 7:00 PM ET
Accepted
Nov 17, 9:07 PM ET
Size
6.5 KB
Accession
0000899243-22-036295
Insider Transaction Report
Form 4
Karydas Daphne
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2022-11-16−12,500→ 0 totalExercise: $0.38Exp: 2032-06-17→ Common Stock (12,500 underlying)
Footnotes (2)
- [F1]The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the 2023 Annual Meeting of Stockholders of LogicBio Therapeutics, Inc.(the "Company'), subject to the Reporting Person's continued service with the Company on the vesting date.
- [F2]Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022, by and among the Company, Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022.
Documents
Issuer
LogicBio Therapeutics, Inc.
CIK 0001664106
Entity typeother
Related Parties
1- filerCIK 0001816952
Filing Metadata
- Form type
- 4
- Filed
- Nov 16, 7:00 PM ET
- Accepted
- Nov 17, 9:07 PM ET
- Size
- 6.5 KB